Galileo Analytics announces world-wide release of Galileo Thermometer

Galileo Analytics today announced the world-wide launch of Galileo Thermometer™, a rapid-turn around platform for providing customized analysis of de-identified electronic health record data from the US and Europe.

Galileo Thermometer™ provides pharmaceutical decision makers with access to custom-designed and developed reports, making it possible to gain a quick read or "temperature check" of specific segments of physicians and patients.

Through a partnership with Cegedim Strategic Data (CSD), Galileo Thermometer™ will draw from de-identified electronic health record data from more than 30 million patients and greater than 30 thousand physicians in the US and the top five markets in Europe.

"For too long, pharmaceutical and biotech companies have been forced to either wait months to gain access to customized market analyses to inform their decisions," said Simon Fitall, CEO of Galileo Analytics. "Often, they don't have that time, so they have to make critical go, no-go decisions amidst a veritable vacuum of information, cobbling together analyst reports or outdated journal articles to inform billion dollar decisions. Galileo Thermometer is designed with these pharma decision makers in mind."

The ease of use, flexibility and speed of Galileo Cosmos™, Galileo Analytics' proprietary visual analytics platform, makes it possible to quickly access, view and analyze even the most complex data sets, while providing the results quickly and at an affordable price.

When combined with Cegedim Strategic Data's extensive, longitudinal, cleansed and normalized data sets, Galileo Thermometer™ will enable all clients to get a quick read on the 'temperature' of the markets they need to assess to inform critical business intelligence and licensing decisions.

Galileo Thermometer Fast, Accurate and Affordable

Galileo Thermometer™ will provide pharma decision makers with the option of purchasing four different levels of reports, depending on the amount of detail they need to inform their decisions. The client will have the ability to determine what data elements are most critical for them for that project, then select the level of report that fits with those needs and their budget.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
RNA-based therapy shows promise in reducing cholesterol and triglycerides